2023年4月25日

分享这篇文章提供的新闻分享本文奥斯汀,得克萨斯州,2023年4月25日,fda批准Vivistim®配对VNS™系统荣获2023枚爱迪生作为一个改变游戏规则的解决方案,帮助中风幸存者生活得更充实的生活。由MicroTransponder®公司,Vivistim采用成对迷走神经刺激与物理或职业疗法帮助缺血性中风幸存者获得2 - 3倍的手和手臂功能比传统康复治疗。爱迪生奖承认创新,帮助人们生活更安全、更健康、更富有成效的生活。MicroTransponder创始人约旦谷类、MBA和Navzer工程师,医学博士,博士接受黄金爱迪生奖Vivistim VNS配对系统,一个改变游戏规则的解决方案,有助于缺血性中风幸存者恢复手和手臂的功能。第一个创新提高中风恢复近30年来的有效性,Vivistim系统成为一个出色的医疗设备爱迪生奖的卫生、医学和生物技术类别之间的近30个决赛选手,赢得金牌的先进治疗最佳新产品奖”目录下。独立判断的资深科学家、设计师、工程师、营销人员和知名学者判断条目在四个标准:概念、价值、交付和影响。建立共同致力于开发解决方案为他们的家庭成员住在一起的衰弱影响中风,MicroTransponder神经科学家和工程师花了15年的团队将神经可塑性的概念转化为一个有时疗法,帮助中风幸存者恢复上肢功能。“这是一个雄心勃勃的旅程但商业化Vivistim系统对我们的团队是一个个人的问题。我们亲眼目睹配对VNS治疗的影响对我们的家庭成员和早期Vivistim用户中风幸存者,”乔丹说谷类,MicroTransponder总统兼联合创始人。“这些Vivistim胜利燃料改善标准的照顾我们的激情所有中风幸存者,给他们新的希望复苏。” Vivistim is ideal for ischemic stroke survivors who have chronic arm and hand deficits six months to 10 years after their stroke. Where previous physical therapy or occupational therapy did not help them make their desired recovery, Paired VNS Therapy enhances the effectiveness of restorative therapy. "It's an honor to celebrate Vivistim winning an Edison Award because it generates even more interest among stroke survivors who will now discover an evidence-based intervention that will help them improve hand and arm function," said Richard Foust, MicroTransponder's CEO. "The Edison Awards recognition parallels the enthusiasm of esteemed healthcare professionals who praise Vivistim for creating a paradigm shift in restoring function after a stroke to help survivors get back to doing the daily activities of living and hobbies they enjoy." To benefit from the Paired VNS Therapy, ischemic stroke survivors will have the small Vivistim device implanted in their upper left chest area during a short outpatient procedure. Once cleared, they engage in physical or occupational therapy where a therapist uses a wireless transmitter to signal the Vivistim device to deliver a gentle pulse to the vagus nerve while the stroke survivor performs a specific task, such as putting on a hat, brushing hair or cutting food. The simultaneous pairing of the functional exercise in high repetitions with vagus nerve stimulation helps increase neuroplasticity and strengthens neural connections to improve upper limb function. "Thomas Edison once shared, 'There's a way to do it better…find it," said Frank Bonafilia, executive director of The Edison Awards. "MicroTransponder is making a tremendous impact in the lives of stroke survivors with the Vivistim Paired VNS System." Premier comprehensive stroke centers and rehabilitation therapy centers across the country now offer the Vivistim System, which can be covered by private insurance or Medicare. Stroke survivors or their caregivers can visit Vivistim.com to learn more about the benefits of Paired VNS Therapy and to connect with a clinical specialist to see if they're a candidate. About MicroTransponder®, Inc. MicroTransponder®, Inc. is a privately held, global medical device company based in Austin, Texas, committed to developing research-based neuroscience solutions. The company focuses on restoring dignity for people suffering from neurological conditions that impair sensory and motor function. MicroTransponder's FDA-approved Vivistim® Paired VNS™ System is a first-of-its-kind, clinically proven medical technology that generates two to three times more improvement in upper limb function than conventional rehabilitation for stroke survivors after six weeks of in-clinic therapy. For more information, visit Vivistim.com . Media Contact: